1. Doxorubicin and zoledronate treatment in a dog with hemophagocytic histiocytic sarcoma.
- Author
-
Soileau AM, Neto RLALT, Jimenez PT, Hamersky J, and Smith AA
- Subjects
- Dogs, Animals, Male, Zoledronic Acid therapeutic use, Lomustine, Doxorubicin therapeutic use, Hyperbilirubinemia drug therapy, Hyperbilirubinemia veterinary, Histiocytic Sarcoma drug therapy, Histiocytic Sarcoma veterinary, Histiocytic Sarcoma pathology, Hypoalbuminemia drug therapy, Hypoalbuminemia veterinary, Thrombocytopenia veterinary, Dog Diseases diagnosis
- Abstract
A 6-year-old castrated male greyhound dog was referred for hemophagocytic histiocytic sarcoma (HHS) diagnosed following splenectomy. Severe thrombocytopenia, mild hypoalbuminemia, mild hypocholesterolemia, and mild hyperbilirubinemia were present. Abdominal ultrasound findings were concerning for hepatic metastasis. Doxorubicin and zoledronate combination therapy was initiated. The dog improved clinically and its thrombocytopenia, hypoalbuminemia, and hyperbilirubinemia resolved. The dog appeared well for 147 d before tumor progression was noted. The dog was treated with lomustine as a final measure, with no response. The dog survived for 6 mo with chemotherapy. To the authors' knowledge, this is the first report of clinical benefit of chemotherapy for HHS. Key clinical message: Doxorubicin should be considered for treating canine HHS since this variant of the disease is historically refractory to lomustine. Further research regarding efficacy of doxorubicin and zoledronate should be pursued., (Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.)
- Published
- 2023